Table 2.
Adjusted hazard ratios (95% confidence intervals) for incident venous thromboembolism comparing new users of specific oral anticoagulants among patients with non-valvular atrial fibrillation, MarketScan databases, 2010 to September 30, 2015.
| Warfarin | Dabigatran | Rivaroxaban | Apixaban | |
|---|---|---|---|---|
| N | 27,065 | 27,065 | ||
| # VTE events | 413 (1.5%) | 214 (0.79%) | ||
| Person-years | 44,169 | 44,386 | ||
| HR (95% CI) | 1.00 (reference) | 0.55 (0.47–0.66) | ||
| N | 22,581 | 22,581 | ||
| # VTE events | 336 (1.5%) | 332 (1.5%) | ||
| Person-years | 26,086 | 26,532 | ||
| HR (95% CI) | 1.00 (reference) | 1.01 (0.87–1.19) | ||
| N | 11,632 | 11,362 | ||
| # VTE events | 157 (1.4%) | 73 (0.63%) | ||
| Person-years | 9,923 | 9,554 | ||
| HR (95% CI) | 1.00 (reference) | 0.51 (0.39–0.68) | ||
| N | 10,580 | 10,580 | ||
| # VTE events | 76 (0.72%) | 160 (1.5%) | ||
| Person-years | 15,234 | 15,126 | ||
| HR (95% CI) | 0.48 (0.36, 0.64) | 1.0 (reference) | ||
| N | 3100 | 3100 | ||
| # VTE events | 20 (0.65%) | 24 (0.77%) | ||
| Person-years | 2,874 | 3,331 | ||
| HR (95% CI) | 1.0 (reference) | 1.06 (0.57–1.95) | ||
| N | 16,234 | 16,234 | ||
| # VTE events | 175 (1.1%) | 98 (0.60%) | ||
| Person-years | 12,632 | 12,477 | ||
| HR (95% CI) | 1.0 (reference) | 0.61 (0.47–0.78) |
Matched 1:1 on HDPS and adjusted for age, sex, CHA2DS2-VASc score and high-dimensional propensity score.
CI: confidence interval; HDPS: high-dimensional propensity scores; HR: hazard ratios; N: number; VTE: venous thromboembolism.